Home > Boards > US OTC > Medical - Healthcare > Wize Pharma Inc. (WIZP)

Second Part of the Glaucoma Phase II study

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 110
Posts 24,076
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2020 4:05:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2020 9:20:44 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/30/2020 5:33:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/9/2020 4:01:03 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/5/2020 5:07:49 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/4/2020 4:03:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/20/2020 4:23:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 2:19:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 2:17:07 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 2:15:45 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/7/2020 4:32:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/6/2020 8:59:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2020 4:28:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/26/2019 4:32:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 12/26/2019 4:31:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2019 9:13:37 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/17/2019 4:59:27 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 12/13/2019 3:01:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/9/2019 5:23:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/5/2019 5:14:59 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2019 4:55:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:25:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:24:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:23:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:15:40 PM
midastouch017   Monday, 12/15/14 08:33:25 AM
Re: None
Post # of 87 
Second Part of the Glaucoma Phase II study has been Approved in a European Country
CF101 is currently one of the few Oral Drugs developed for Glaucoma
A US Patent for the utilization of CF101 for Glaucoma Treatment will be Valid until 2030

The Glaucoma Market Size is estimated to be approximately $3B

PETACH TIKVA, Israel, Dec. 15, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (CFBI.TA), (NYSE MKT: CANF), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, and its subsidiary, OphthaliX Inc. (OPLI), jointly announced today the receipt of an approval from the regulatory authorities in Bulgaria to initiate the enrollment of patients to the second cohort of the Phase II clinical study in glaucoma. OphthaliX plans to conduct the study in two European countries, Bulgaria and Romania. The approval in Romania is expected shortly.

In the first cohort of this study, patients were treated with 1 mg CF101 and placebo. Blinded results from this cohort showed that the drug had a favorable safety profile and was well tolerated. In the current cohort, the CF101 dose will be increased to 2 mg based on positive linear interim data in Can-Fite's Phase II/III Psoriasis study.

The rationale to treat glaucoma patients with CF101 stems from data in another ophthalmic study showing that CF101 lowered the intraocular pressure (IOP) in patient eyes. Subjects will be randomized to receive 2 mg CF101 or matching placebo, given orally every 12 hours for 16 weeks. The study data will be released upon completion of the 2 mg dose treatment group, and is expected to be announced during the second half of 2015.

OphthaliX has the exclusive rights for the use and development of CF101 in the field of ophthalmic diseases, which includes a US patent for the reduction of IOP that expires in 2030. Increased IOP is the most important and only modifiable risk factor for glaucoma.

As previously announced, OphthaliX received third-party validation of its technology for the utilization of A3 adenosine receptor agonists for lowering intraocular pressure and treating glaucoma that was published by Professor M. Francesca Cordeiro, a Professor of Glaucoma & Retinal Neuro-degeneration at the University College of London and Imperial College in London.

The global glaucoma market size is estimated by GlobalData to be worth approximately $3B, where most of the drugs are generic ones and are given as eye drops. The key advantage of CF101 is its oral administration which contributes to better compliance.

About CF101

CF101, an A3 adenosine receptor (A3AR) agonist, is a novel, first in class small molecule orally bioavailable drug which binds with high affinity and selectivity to the A3AR, which is known to be over-expressed in inflammatory cells. The drug acts as a neuro-protective agent and prevents apoptosis of retinal ganglion cells.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

About OphthaliX Inc.

OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist